Clinical Trials Logo

Filter by:
NCT ID: NCT04847024 Completed - Clinical trials for Caesarean Section; Pain

Parecoxib vs. Dexketoprofen for the Management of Pain After Cesarean Section.

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

Although it is known that parecoxib and dexketoprofen are commonly used in successful post-operative pain relief, there are very few studies that compare these two agents in their individual applications and/or combined with neuraxial analgesia with opioids and even less in post-cesarean section pain, as well as the evaluation of the side effects and their impact on the patient's functionality. For this reason, in order to approach this answer, we sought to perform this study in patients undergoing elective or emergency cesarean section in our institution, who meet the inclusion criteria, using the Visual Analog Pain Scale at 12 hrs and 24 hrs post surgery and evaluating the aforementioned side effects, comparing in one arm of the study Parecoxib + acetaminophen vs Dexketoprofen + acetaminophen in the other arm, randomizing the patients in both groups using a double-blind configuration.

NCT ID: NCT04814134 Recruiting - Clinical trials for Acute Decompensated Heart Failure

CPNS Pilot Study: Evaluation of Safety and Performance of the Cardiac Pulmonary Nerve Stimulation (CPNS) System in Patients With ADHF

Start date: April 9, 2021
Phase: N/A
Study type: Interventional

The CPNS Pilot Study: An evaluation of the safety and performance of the Cardionomic Cardiac Pulmonary Nerve Stimulation (CPNS) system in patients with acute decompensated heart failure.

NCT ID: NCT04791020 Recruiting - Pain Clinical Trials

Topic Cervical Anesthesia Plus Paracervical Blockade for Pain Control During Endouterine Manual Aspiration

Start date: March 8, 2021
Phase: N/A
Study type: Interventional

To compare the effectiveness of lidocaine gel plus paracervical blockade vs. lidocaine gel alone in the management of pain during endouterine manual aspiration.

NCT ID: NCT04764188 Not yet recruiting - NSCLC Clinical Trials

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

Start date: April 2, 2021
Study type: Observational

This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.

NCT ID: NCT04672395 Not yet recruiting - COVID-19 Clinical Trials

A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19

Start date: March 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this double-blind, randomized, controlled study is to evaluate the efficacy, immunogenicity, reactogenicity and safety of an adjuvanted recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) trimeric spike (S)-protein subunit vaccine (SCB-2019) for the prevention of SARS-CoV-2-mediated COVID-19 in adult subjects 18 years of age and above.

NCT ID: NCT04605159 Recruiting - Clinical trials for Respiratory Syncytial Virus Infections

A Phase III Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

Start date: November 20, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the ability of a single dose of the investigational RSV Maternal vaccine, administered intramuscularly to pregnant women aged 18-49 years, in good general maternal health, in preventing medically assessed RSV associated Lower Respiratory Tract Illnesses (LRTIs) in infants born to vaccinated mothers. The study will also evaluate the safety of the investigational RSV Maternal vaccine both in vaccinated mothers and in their corresponding infant.

NCT ID: NCT04583280 Recruiting - Clinical trials for Respiratory Tract Infections

A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)

Start date: January 29, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy of rilematovir compared to placebo treatment with respect to the clinical outcome on the RSV Recovery Scale (RRS).

NCT ID: NCT04566484 Not yet recruiting - Chikungunya Clinical Trials

Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia

Start date: July 1, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This study has a Phase II with part A and part B and a Phase III with part C. This Adaptive seamless design will prospectively include planned modifications and incorporate both dose selection (parts A and B) and confirmation of the selected dose (part C) based on the accumulation of subjects' data within the entire study period as shown below. Part C will be randomized for immunogenicity subset and will be open label for safety cohort. The participants assigned to the control group from all parts (i.e, Part A, B and C) will be continuously followed up from the enrollment until the end of the study.

NCT ID: NCT04524416 Recruiting - Ocular Hypertension Clinical Trials

MINIject Global Long-Term Follow-up Study

Start date: August 5, 2020
Study type: Observational

The study will assess the long-term (up to 5 years) safety and performance in patients with open-angle glaucoma uncontrolled by topical hypotensive medications who had previously been implanted with a MINIject glaucoma implant.

NCT ID: NCT04515186 Recruiting - Clinical trials for Cutaneous Leishmaniases

Combination, Miltefosine Monotherapy & Antimonial Therapy for Cutaneous Leishmaniasis in New World

Start date: January 26, 2021
Phase: Phase 3
Study type: Interventional

This study evaluates if the combination of thermotherapy (one application, 50⁰C for 30") and 3 weeks of miltefosine is safe and have a comparable cure rate with the current recommended first line treatments comprising meglumine antimoniate for 3 weeks or miltefosine monotherapy for 4 weeks, for the treatment of uncomplicated cutaneous leishmaniasis cases in the New World.